Interview with Michele Garot, Vice President, BeCRO
What was the motivation behind the establishment of BeCRO and why was it only established in 2010 given the strength of Belgium’s clinical trials industry? Philippe van der Hofstadt: Prior…
Address: Sint lambertusstraat 141 Rue Saint LambertB- 1200 Brussels,Belgium
Tel:
Web: http://www.becro.be/
BeCRO is the Belgian Association of CRO’s. BeCRO was initially founded by 19 member companies and has now grown to include 32 active members, representing more than a third of the 83 identified CRO’s in the country in 2011.
The aims of BeCRO are:
– To establish an association of service and consultancy companies active in pharmaceutical and medical development for health products, companies involved in the running of complete preclinical or clinical trials or parts thereof,- To represent and defend the interests of such companies to health authorities, companies, institutions and organisations operating in the health sector,- To be recognised as a privileged interlocutor by health authorities, any professional bodies and any national or international association and/or federation,- To establish good operating practices, with respect as regards highest quality rules and Good Clinical Practices,- To work towards training its members,- To promote the association.
What was the motivation behind the establishment of BeCRO and why was it only established in 2010 given the strength of Belgium’s clinical trials industry? Philippe van der Hofstadt: Prior…
A roundup of some of the biggest pharma news from Belgium including Neuraxpharm’s new Belgian affiliate, Novalis Biotech’s investment in Rarity Bioscience, Catalent’s plasmid DNA manufacturing site and a recent…
Edward Mc Gettrick and Sharon Gorman of Pfizer, writing in the January 2023 edition of DIA’s Global Forum magazine, examine the scope and impact of the European Union’s new Regulation on…
Based on current discussions by the European Commission, launch conditionalities would not account for the distinct nature of small and mid-sized companies, OMPs and ATMPs. EUCOPE’s Alexander Natz breaks down…
Writing in the special December 2022 edition of DIA’s Global Forum magazine, Eli Lilly’s Mark Mayer, Pfizer’s Nick Sykes and Julie O’Brien, and the EFPIA’s Sini Eskola, Magda Chlebus, and…
Writing in the DIA Global Forum’s special November 2022 issue on the Digital Virtuous Loop Karin Van Baelen and Susan Sandler – both of Janssen – and AbbVie’s Álmath Spooner…
The EU biopharmaceutical ecosystem is currently languishing in third place globally. EUCOPE’s Alexander Natz discusses how the European Commission’s most fundamental review of the pharmaceutical legislation in decades is supposed…
EUCOPE’s Secretary-General Dr. Alexander Natz sees both opportunities and pitfalls with the EU HTA procedure, saying that the next three years will decide the crucial steps and whether the new…
In an extensive recent PharmaBoardroom conversation, EMA Head of Advanced Therapies Ana-Hidalgo-Simon highlighted some of the most important trends around advanced therapy regulation in Europe. Hidalgo-Simon touched on why moderate…
Speaking exclusively to PharmaBoardroom, the EMA’s Head of Advanced Therapies Ana Hidalgo-Simon discusses steadily growing numbers of regulatory applications in the advanced therapy field, the vital importance of patient group…
Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up…
The new Belgian government has moved to streamline its response to the COVID-19 crisis with the appointment of Pedro Facon, director general for health at Belgium’s Federal Public Service Health…
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
See our Cookie Privacy Policy Here
